Journal
APMIS
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1111/apm.13316
Keywords
Invasive aspergillosis; fungal infection; antifungal therapy
Categories
Ask authors/readers for more resources
The prevalence of invasive pulmonary aspergillosis (IPA) is increasing in critically ill patients, both immunocompetent and immunocompromised. It commonly occurs as a complication of severe influenza and severe COVID-19 infection. IPA remains challenging to diagnose and treat and is associated with significant morbidity and mortality.
The prevalence of invasive pulmonary aspergillosis (IPA) is growing in critically ill patients in the intensive care unit (ICU). It is increasingly recognized in immunocompetent hosts and immunocompromised ones. IPA frequently complicates both severe influenza and severe coronavirus disease 2019 (COVID-19) infection. It continues to represent both a diagnostic and therapeutic challenge and can be associated with significant morbidity and mortality. In this narrative review, we describe the epidemiology, risk factors and disease manifestations of IPA. We discuss the latest evidence and current published guidelines for the diagnosis and management of IPA in the context of the critically ill within the ICU. Finally, we review influenza-associated pulmonary aspergillosis (IAPA), COVID-19-associated pulmonary aspergillosis (CAPA) as well as ongoing and future areas of research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available